Andrea S. Henden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrea S. Henden has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
- Geoffrey R. Hill
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
5 shared publications - Siok-Keen Tey
QIMR Berghofer Medical Research Institute, Brisbane, Australia
5 shared publications - Antiopi Varelias
Transplantation Immunology Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia
4 shared publications Glen A. Kennedy
Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia; The University of Queensland, Faculty of Health Medicine and Behavioural Sciences
4 shared publicationsAndrew D. Clouston
Envoi Pathology, Brisbane, QLD, Australia
3 shared publications- Ashleigh P. Scott
Haematology and Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
3 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Wiley in Internal Medicine Journal
Preventing infections after CD19‐directed chimeric antigen receptor T‐cell therapies for lymphoma: a consensus practice statement
Chimeric antigen receptor (CAR) T‐cell therapies directed against c luster of differentiation 19 ( CD19) are a standard of care for relapsed or refractory B‐cell lymphomas. Infection is the leading cause of non‐relapse mortality, and this risk may persist for years after CAR T‐cell receipt. Recipients of CAR T‐cells can present in various clinical settings, and few trials have prospectively assessed prevention and management of infection in this group. This position statement provides Australian and New Zealand clinicians with a rational approach to preventing, investigating and managing infections after CD19‐directed CAR T‐cell therapy for lymphoma.
- 30 September 2026
- Published by Wiley in Internal Medicine Journal
Open AccessPreventing infections after CD19‐directed chimeric antigen receptor T‐cell therapies for lymphoma: a consensus practice statement
Chimeric antigen receptor (CAR) T‐cell therapies directed against c luster of differentiation 19 ( CD19) are a standard of care for relapsed or refractory B‐cell lymphomas. Infection is the leading cause of non‐relapse mortality, and this risk may persist for years after CAR T‐cell receipt. Recipients of CAR T‐cells can present in various clinical settings, and few trials have prospectively assessed prevention and management of infection in this group. This position statement provides Australian and New Zealand clinicians with a rational approach to preventing, investigating and managing infections after CD19‐directed CAR T‐cell therapy for lymphoma.
- Open Access
- 10 September 2026
- Published by Wiley in Internal Medicine Journal
ANZTCT cytomegalovirus practice survey for allogeneic haemopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand
Background: Despite pre‐emptive treatment (PeT), cytomegalovirus (CMV) disease and reactivation remain a clinical concern. In Australia and New Zealand (ANZ), variability exists in the management of CMV for haematopoietic stem cell transplantation (HSCT) recipients. Aims and Methods: To understand the state of practice in Australia, a survey captured insights on detection, monitoring, prophylaxis and treatment from 21 sites, including 11 chimeric antigen receptor T‐cell (CAR‐T) therapy sites. Results: Respondents reported 26 cases of CMV disease after HSCT and four cases after CAR‐T in 2024. All HSCT sites and four CAR‐T sites had CMV protocols. Commonly, CMV nucleic acid viral load (VL) testing was employed weekly. Sites utilised plasma (66%) or whole blood (33%). VL was reported as IU/mL (66%), copies/mL (29%) or not specified (5%). One third of respondents tested CMV DNAemia before HSCT. All recipients were monitored regardless of CMV serostatus. Half the sites employed post‐HSCT CMV prophylaxis using letermovir (nine sites), (val)aciclovir (eight) and (val)ganciclovir (three). VL thresholds for PeT ranged from 100 to 5000 IU/mL. Most sites used (val)ganciclovir for PeT, with foscarnet second line. At 76% of HSCT sites, PeT continued until two consecutive negative results. Frontline therapy for CMV disease is ganciclovir; 86% of ANZ sites used (val)ganciclovir while three paediatric sites used foscarnet. For resistant or refractory CMV, guidelines recommend foscarnet or maribavir, although maribavir was not funded or used during the survey period. CMV‐specific immunotherapy can be considered. Conclusions: Institutional preferences and medicine funding drives variability in ANZ practice. This leaves potential for healthcare inequity since newer antiviral agents are inconsistently used, contrasting with international guidelines.
- 10 September 2026
- Published by Wiley in Internal Medicine Journal
Open AccessANZTCT cytomegalovirus practice survey for allogeneic haemopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand
Background: Despite pre‐emptive treatment (PeT), cytomegalovirus (CMV) disease and reactivation remain a clinical concern. In Australia and New Zealand (ANZ), variability exists in the management of CMV for haematopoietic stem cell transplantation (HSCT) recipients. Aims and Methods: To understand the state of practice in Australia, a survey captured insights on detection, monitoring, prophylaxis and treatment from 21 sites, including 11 chimeric antigen receptor T‐cell (CAR‐T) therapy sites. Results: Respondents reported 26 cases of CMV disease after HSCT and four cases after CAR‐T in 2024. All HSCT sites and four CAR‐T sites had CMV protocols. Commonly, CMV nucleic acid viral load (VL) testing was employed weekly. Sites utilised plasma (66%) or whole blood (33%). VL was reported as IU/mL (66%), copies/mL (29%) or not specified (5%). One third of respondents tested CMV DNAemia before HSCT. All recipients were monitored regardless of CMV serostatus. Half the sites employed post‐HSCT CMV prophylaxis using letermovir (nine sites), (val)aciclovir (eight) and (val)ganciclovir (three). VL thresholds for PeT ranged from 100 to 5000 IU/mL. Most sites used (val)ganciclovir for PeT, with foscarnet second line. At 76% of HSCT sites, PeT continued until two consecutive negative results. Frontline therapy for CMV disease is ganciclovir; 86% of ANZ sites used (val)ganciclovir while three paediatric sites used foscarnet. For resistant or refractory CMV, guidelines recommend foscarnet or maribavir, although maribavir was not funded or used during the survey period. CMV‐specific immunotherapy can be considered. Conclusions: Institutional preferences and medicine funding drives variability in ANZ practice. This leaves potential for healthcare inequity since newer antiviral agents are inconsistently used, contrasting with international guidelines.
- 7 May 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (19) , 2272-2277
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
In this retrospective analysis of 584 patients who received chimeric antigen receptor T-cell therapy for large B-cell lymphoma at 6 Australian centers, no association was found between time of infusion and outcome, accounting for confounders, suggesting minimal clinical impact of chronobiology in this setting.
- 7 May 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (19) , 2272-2277
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
In this retrospective analysis of 584 patients who received chimeric antigen receptor T-cell therapy for large B-cell lymphoma at 6 Australian centers, no association was found between time of infusion and outcome, accounting for confounders, suggesting minimal clinical impact of chronobiology in this setting.
- Open Access
Prospective Biomarkers of SARS-CoV-2 Vaccine Seroconversion in Patients with Haematological Malignancies
Background: SARS-CoV-2 vaccination is crucial for protecting against severe COVID-19 disease; however, patients with haematological malignancies (HM) respond poorly to vaccination due to immunosuppression driven by chemotherapy, targeted cell depletion, and immune dysregulation. We sought to define novel biomarkers that predict effective vaccination in patients with HM. Methods: HM patients and healthy controls received SARS-CoV-2 vaccines and were followed for six months post-vaccination. Virus-specific humoral and cellular immune responses were analysed in serum and whole blood pre- and post-vaccination, and serum proteomics was analysed pre-vaccination to identify potential biomarkers for vaccine response. Results: HM patients displayed delayed antibody seroconversion, and 37.5% failed to seroconvert. Baseline proteomic and cellular immune profiles revealed that T-cell-associated chemokines CXCL13 and CRTAM were differentially expressed, with decreased levels seen in vaccine non-responders. Vaccine response was also associated with a reduced frequency of circulating monocytes, greater numbers of B-cells, and a trend toward greater numbers of CD4+ helper cell phenotypes, including T peripheral helper cells pre-vaccination. In vitro generation of COVID-19-specific T-cells from a subset of participants trended towards increased cytotoxic CD4+ and CD8+ T-cell activity in seroconverters and dysfunctional COVID-19-specific T-cell responses in non-seroconverters. Conclusions: These results suggest that HM patients have impaired T-cell immunity, and non-responders may be identified by low levels of serum CXCL13 and CRTAM. This allows for the identification of at-risk patients who would benefit from alternative COVID-19 prophylaxis strategies.
Open AccessProspective Biomarkers of SARS-CoV-2 Vaccine Seroconversion in Patients with Haematological Malignancies
Background: SARS-CoV-2 vaccination is crucial for protecting against severe COVID-19 disease; however, patients with haematological malignancies (HM) respond poorly to vaccination due to immunosuppression driven by chemotherapy, targeted cell depletion, and immune dysregulation. We sought to define novel biomarkers that predict effective vaccination in patients with HM. Methods: HM patients and healthy controls received SARS-CoV-2 vaccines and were followed for six months post-vaccination. Virus-specific humoral and cellular immune responses were analysed in serum and whole blood pre- and post-vaccination, and serum proteomics was analysed pre-vaccination to identify potential biomarkers for vaccine response. Results: HM patients displayed delayed antibody seroconversion, and 37.5% failed to seroconvert. Baseline proteomic and cellular immune profiles revealed that T-cell-associated chemokines CXCL13 and CRTAM were differentially expressed, with decreased levels seen in vaccine non-responders. Vaccine response was also associated with a reduced frequency of circulating monocytes, greater numbers of B-cells, and a trend toward greater numbers of CD4+ helper cell phenotypes, including T peripheral helper cells pre-vaccination. In vitro generation of COVID-19-specific T-cells from a subset of participants trended towards increased cytotoxic CD4+ and CD8+ T-cell activity in seroconverters and dysfunctional COVID-19-specific T-cell responses in non-seroconverters. Conclusions: These results suggest that HM patients have impaired T-cell immunity, and non-responders may be identified by low levels of serum CXCL13 and CRTAM. This allows for the identification of at-risk patients who would benefit from alternative COVID-19 prophylaxis strategies.
- Open Access
- 12 February 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (3) , 981-991
Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice
Summary: Febrile neutropenia causes substantial morbidity in acute myeloid leukaemia and higher risk myelodysplastic syndrome. We aimed to describe current practice and priorities for clinical trials in the prevention and management of febrile neutropenia across Australia/New Zealand (ANZ), the United Kingdom (UK), Canada and Europe. We performed an international survey of haematologists recruited via professional networks. Eighty‐five unique hospitals were represented (ANZ = 20; Canada = 14; UK = 30; Europe = 21). Antibacterial prophylaxis was more commonly prescribed in Canada (79%) and the UK (83%) than in ANZ (30%) and Europe (48%, p < 0.001), and was prescribed more frequently to outpatients than inpatients. The most common empiric treatment was piperacillin–tazobactam monotherapy (66/84, 79%), with nurse‐initiated antibiotic orders used in 35/84 (42%). Screening for multidrug‐resistant organisms varied and was not usually used to direct antibiotic treatment. Antibiotic de‐escalation was attempted in most institutions; for uncomplicated short‐lived fever of unknown source, 39/85 (46%) reported ceasing antibiotics at 72 h and 68/85 (80%) within 7 days. For patients with bacteraemia, de‐escalation strategies included narrowing spectrum, oral switch and cessation after defined duration. Most respondents (79/85, 93%) reported interest in recruiting for clinical trials. Clinical trials addressing practice variability in febrile neutropenia are needed, and are supported by haematologists.
- 12 February 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (3) , 981-991
Open AccessPrevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice
Summary: Febrile neutropenia causes substantial morbidity in acute myeloid leukaemia and higher risk myelodysplastic syndrome. We aimed to describe current practice and priorities for clinical trials in the prevention and management of febrile neutropenia across Australia/New Zealand (ANZ), the United Kingdom (UK), Canada and Europe. We performed an international survey of haematologists recruited via professional networks. Eighty‐five unique hospitals were represented (ANZ = 20; Canada = 14; UK = 30; Europe = 21). Antibacterial prophylaxis was more commonly prescribed in Canada (79%) and the UK (83%) than in ANZ (30%) and Europe (48%, p < 0.001), and was prescribed more frequently to outpatients than inpatients. The most common empiric treatment was piperacillin–tazobactam monotherapy (66/84, 79%), with nurse‐initiated antibiotic orders used in 35/84 (42%). Screening for multidrug‐resistant organisms varied and was not usually used to direct antibiotic treatment. Antibiotic de‐escalation was attempted in most institutions; for uncomplicated short‐lived fever of unknown source, 39/85 (46%) reported ceasing antibiotics at 72 h and 68/85 (80%) within 7 days. For patients with bacteraemia, de‐escalation strategies included narrowing spectrum, oral switch and cessation after defined duration. Most respondents (79/85, 93%) reported interest in recruiting for clinical trials. Clinical trials addressing practice variability in febrile neutropenia are needed, and are supported by haematologists.
- 15 January 2025
- Published by University of Queensland Library
Anti-leukaemia effect of Interferons
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.
- 15 January 2025
- Published by University of Queensland Library
Anti-leukaemia effect of Interferons
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.
- Open Access
- 1 January 2025
- Published by Wiley in Clinical & Translational Immunology
- Vol. 14 (6) , e70038
Allogeneic ‘off‐the‐shelf’ SARS‐CoV‐2‐specific adoptive T‐cell therapy for refractory viral infection and end organ disease
Objectives: Despite the effective roll‐out of COVID‐19 vaccines, immunocompromised patients have a higher risk of morbidity and mortality following SARS‐CoV‐2 infection. Allogeneic adoptive T‐cell immunotherapy is now established as an effective approach to treat viral diseases in immunocompromised patients. The objective of this study was to assess the safety of allogeneic virus‐specific T‐cell therapy in patients with COVID‐19.Methods: Using a repository of SARS‐CoV‐2‐specific T cells generated from healthy exposed volunteers, we conducted an open‐label phase I trial to assess the feasibility and safety of allogeneic SARS‐CoV‐2‐specific T cells in immune‐compromised cancer patients with COVID‐19.Results: Six participants at risk of severe COVID‐19 were enrolled and received SARS‐CoV‐2‐specific T‐cell therapy within 4 days of recruitment. The first five participants who received two infusions of allogeneic SARS‐CoV‐2‐specific T‐cell therapy experienced no adverse events following treatment. Four of the six participants showed improvement in viral load following treatment and were alive at 12‐week follow‐up. One participant died 6 days after their second infusion, because of established pulmonary parenchymal damage following prolonged COVID infection. Another, who had underlying lupus nephritis, developed cytokine release syndrome and diffuse alveolar haemorrhage following a single infusion and was withdrawn from the study. They subsequently recovered from this serious adverse event.Conclusion: Allogeneic SARS‐CoV‐2‐specific T‐cell therapy provides a platform to rapidly administer T cells to high‐risk COVID‐19 patients. It was associated with a reduced viral load and increased SARS‐CoV‐2‐specific T‐cell responses in the majority of treated patients.
- 1 January 2025
- Published by Wiley in Clinical & Translational Immunology
- Vol. 14 (6) , e70038
Open AccessAllogeneic ‘off‐the‐shelf’ SARS‐CoV‐2‐specific adoptive T‐cell therapy for refractory viral infection and end organ disease
Objectives: Despite the effective roll‐out of COVID‐19 vaccines, immunocompromised patients have a higher risk of morbidity and mortality following SARS‐CoV‐2 infection. Allogeneic adoptive T‐cell immunotherapy is now established as an effective approach to treat viral diseases in immunocompromised patients. The objective of this study was to assess the safety of allogeneic virus‐specific T‐cell therapy in patients with COVID‐19.Methods: Using a repository of SARS‐CoV‐2‐specific T cells generated from healthy exposed volunteers, we conducted an open‐label phase I trial to assess the feasibility and safety of allogeneic SARS‐CoV‐2‐specific T cells in immune‐compromised cancer patients with COVID‐19.Results: Six participants at risk of severe COVID‐19 were enrolled and received SARS‐CoV‐2‐specific T‐cell therapy within 4 days of recruitment. The first five participants who received two infusions of allogeneic SARS‐CoV‐2‐specific T‐cell therapy experienced no adverse events following treatment. Four of the six participants showed improvement in viral load following treatment and were alive at 12‐week follow‐up. One participant died 6 days after their second infusion, because of established pulmonary parenchymal damage following prolonged COVID infection. Another, who had underlying lupus nephritis, developed cytokine release syndrome and diffuse alveolar haemorrhage following a single infusion and was withdrawn from the study. They subsequently recovered from this serious adverse event.Conclusion: Allogeneic SARS‐CoV‐2‐specific T‐cell therapy provides a platform to rapidly administer T cells to high‐risk COVID‐19 patients. It was associated with a reduced viral load and increased SARS‐CoV‐2‐specific T‐cell responses in the majority of treated patients.
- Open Access
- 1 April 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (7)
IL-6–mediated endothelial injury impairs antiviral humoral immunity after bone marrow transplantation
Endothelial function and integrity are compromised after allogeneic bone marrow transplantation (BMT), but how this affects immune responses broadly remains unknown. Using a preclinical model of CMV reactivation after BMT, we found compromised antiviral humoral responses induced by IL-6 signaling. IL-6 signaling in T cells maintained Th1 cells, resulting in sustained IFN-γ secretion, which promoted endothelial cell (EC) injury, loss of the neonatal Fc receptor (FcRn) responsible for IgG recycling, and rapid IgG loss. T cell–specific deletion of IL-6R led to persistence of recipient-derived, CMV-specific IgG and inhibited CMV reactivation. Deletion of IFN-γ in donor T cells also eliminated EC injury and FcRn loss. In a phase III clinical trial, blockade of IL-6R with tocilizumab promoted CMV-specific IgG persistence and significantly attenuated early HCMV reactivation. In sum, IL-6 invoked IFN-γ–dependent EC injury and consequent IgG loss, leading to CMV reactivation. Hence, cytokine inhibition represents a logical strategy to prevent endothelial injury, thereby preserving humoral immunity after immunotherapy.
- 1 April 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (7)
Open AccessIL-6–mediated endothelial injury impairs antiviral humoral immunity after bone marrow transplantation
Endothelial function and integrity are compromised after allogeneic bone marrow transplantation (BMT), but how this affects immune responses broadly remains unknown. Using a preclinical model of CMV reactivation after BMT, we found compromised antiviral humoral responses induced by IL-6 signaling. IL-6 signaling in T cells maintained Th1 cells, resulting in sustained IFN-γ secretion, which promoted endothelial cell (EC) injury, loss of the neonatal Fc receptor (FcRn) responsible for IgG recycling, and rapid IgG loss. T cell–specific deletion of IL-6R led to persistence of recipient-derived, CMV-specific IgG and inhibited CMV reactivation. Deletion of IFN-γ in donor T cells also eliminated EC injury and FcRn loss. In a phase III clinical trial, blockade of IL-6R with tocilizumab promoted CMV-specific IgG persistence and significantly attenuated early HCMV reactivation. In sum, IL-6 invoked IFN-γ–dependent EC injury and consequent IgG loss, leading to CMV reactivation. Hence, cytokine inhibition represents a logical strategy to prevent endothelial injury, thereby preserving humoral immunity after immunotherapy.